PURPOSE: A high percentage of paragangliomas express somatostatin receptors that can be utilized for targeted radioisotope therapy. The aim of this study was to describe and discuss the challenges of treating these tumors with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) radioisotope therapy using established protocols. METHODS AND RESULTS: Three paraganglioma patients were treated with 4-5 cycles of (177)Lu-DOTATATE and were evaluated for side effects and response to therapy. Two of the three patients developed severe adverse reactions following their first (177)Lu-DOTATATE treatment. One patient developed a catecholamine crisis and tumor lysis syndrome within hours of treatment, requiring intensive care unit (ICU) support, and another developed a catecholamine crisis 3 days after treatment, requiring hospitalization. The treatment protocols at our institution were subsequently modified by increasing the radioisotope infusion time from 15 to 30 min, as recommended in the literature, to 2-4 h and by reducing the administered dose of (177)Lu-DOTATATE. Subsequent (177)Lu-DOTATATE treatments utilizing the modified protocols were well tolerated, and response to therapy was achieved in all three patients, resulting in significantly improved quality of life. CONCLUSION: (177)Lu-DOTATATE is an exciting new therapeutic option in the management of paragangliomas; however, current treatment protocols described in the literature may need to be modified by lengthening the infusion time and/or lowering the initial treatment dose to prevent or reduce the severity of adverse reactions.
PURPOSE: A high percentage of paragangliomas express somatostatin receptors that can be utilized for targeted radioisotope therapy. The aim of this study was to describe and discuss the challenges of treating these tumors with (177)Lu-[DOTA(0),Tyr(3)]octreotate (DOTATATE) radioisotope therapy using established protocols. METHODS AND RESULTS: Three paragangliomapatients were treated with 4-5 cycles of (177)Lu-DOTATATE and were evaluated for side effects and response to therapy. Two of the three patients developed severe adverse reactions following their first (177)Lu-DOTATATE treatment. One patient developed a catecholamine crisis and tumor lysis syndrome within hours of treatment, requiring intensive care unit (ICU) support, and another developed a catecholamine crisis 3 days after treatment, requiring hospitalization. The treatment protocols at our institution were subsequently modified by increasing the radioisotope infusion time from 15 to 30 min, as recommended in the literature, to 2-4 h and by reducing the administered dose of (177)Lu-DOTATATE. Subsequent (177)Lu-DOTATATE treatments utilizing the modified protocols were well tolerated, and response to therapy was achieved in all three patients, resulting in significantly improved quality of life. CONCLUSION: (177)Lu-DOTATATE is an exciting new therapeutic option in the management of paragangliomas; however, current treatment protocols described in the literature may need to be modified by lengthening the infusion time and/or lowering the initial treatment dose to prevent or reduce the severity of adverse reactions.
Authors: Karel Pacak; Graeme Eisenhofer; Håkan Ahlman; Stefan R Bornstein; Anne-Paule Gimenez-Roqueplo; Ashley B Grossman; Noriko Kimura; Massimo Mannelli; Anne Marie McNicol; Arthur S Tischler Journal: Nat Clin Pract Endocrinol Metab Date: 2007-02
Authors: Damian Wild; Jörg S Schmitt; Mihaela Ginj; Helmut R Mäcke; Bert F Bernard; Eric Krenning; Marion De Jong; Sandra Wenger; Jean-Claude Reubi Journal: Eur J Nucl Med Mol Imaging Date: 2003-08-21 Impact factor: 9.236
Authors: Dik J Kwekkeboom; Wouter W de Herder; Boen L Kam; Casper H van Eijck; Martijn van Essen; Peter P Kooij; Richard A Feelders; Maarten O van Aken; Eric P Krenning Journal: J Clin Oncol Date: 2008-05-01 Impact factor: 44.544
Authors: Klaas Pieter Koopmans; Pieter L Jager; Ido P Kema; Michiel N Kerstens; Frans Albers; Robin P F Dullaart Journal: J Nucl Med Date: 2008-07-16 Impact factor: 10.057
Authors: Michael B Davidson; Snehal Thakkar; John K Hix; Naveen D Bhandarkar; Alan Wong; Martin J Schreiber Journal: Am J Med Date: 2004-04-15 Impact factor: 4.965
Authors: Alexandra L Tabakin; Michael A Weintraub; Kushan D Radadia; Cristo G Salazar; Evita Sadimin; Eric A Singer Journal: Clin Oncol (Belmont) Date: 2019-03-08
Authors: Camilo Jimenez; Guofan Xu; Jeena Varghese; Paul H Graham; Matthew T Campbell; Yang Lu Journal: Curr Oncol Rep Date: 2022-01-21 Impact factor: 5.075
Authors: Jorge A Carrasquillo; Clara C Chen; Abhishek Jha; Karel Pacak; Daniel A Pryma; Frank I Lin Journal: J Nucl Med Date: 2021-09-01 Impact factor: 10.057
Authors: Neeta Pandit-Taskar; Karel Pacak; Abhishek Jha; David Taïeb; Jorge A Carrasquillo; Daniel A Pryma; Mayank Patel; Corina Millo; Wouter W de Herder; Jaydira Del Rivero; Joakim Crona; Barry L Shulkin; Irene Virgolini; Alice P Chen; Bhagwant R Mittal; Sandip Basu; Joseph S Dillon; Thomas A Hope; Carina Mari Aparici; Andrei H Iagaru; Rodney J Hicks; Anca M Avram; Jonathan R Strosberg; Ali Cahid Civelek; Frank I Lin Journal: Clin Cancer Res Date: 2021-03-08 Impact factor: 13.801
Authors: Franz Sesti; Tiziana Feola; Giulia Puliani; Roberta Centello; Valentina Di Vito; Oreste Bagni; Andrea Lenzi; Andrea M Isidori; Vito Cantisani; Antongiulio Faggiano; Elisa Giannetta Journal: Front Oncol Date: 2021-06-17 Impact factor: 6.244
Authors: M Albertelli; A Dotto; C Di Dato; P Malandrino; R Modica; A Versari; A Colao; D Ferone; A Faggiano Journal: Rev Endocr Metab Disord Date: 2021-09 Impact factor: 9.306